Bone
01 Jan 2013
Tumour regression & tissue repair when ZOL is combined with IFO in rat osteosarcoma
Aim: To evaluate the efficacy of the combination of zoledronic acid (ZOL) with ifosfamide (IFO) on local tumor growth, histologic response, and animal survival using a rat-transplantable model of osteosarcoma. Conclusions: This is the first report of the anti-bone resorption and antitumoral activities of zoledronic acid in a rat model…
Cancer
01 Jan 2013
CIBO-P for pts with poor prognostic refractory or multiple disease recurrent aggressive NHL
Aim: To assess the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive NHL, to evaluate the long-term results, and identify prognostic factors in the study cohort. Conclusions: In the current study, CIBO-P was a novel, highly active, and safe combination therapy for patients…
Cancer
01 Jan 2013
IMVP-16/Pd followed by HDC/ASCT for relapsed peripheral T-cell lymphomas
Aim: To analyse the treatment outcome of IMVP-16/Pd (ifosfamide, methotrexate, etoposide and prednisone) followed by high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with peripheral T-cell lymphomas (PTCLs) who were previously treated with CHOP. Conclusions: These results indicate that IMVP-16/Pd followed by HDC/ASCT appears to be an effective…
Cancer
01 Jan 2013
Phase 2 study of DICb in adv. NSCLC
Aim: To test the tolerability and activity of a novel regimen combining docetaxel instead of paclitaxel and carboplatin instead of cisplatin with ifosfamide (DICb) in the outpatient setting in patients with advanced non-small cell lung cancer. Conclusions: In the present phase II study the DICb combination yielded important activity and…
Cancer
01 Jan 2013
CEBOPP/VIML Followed by Radiotherapy for Intermediate- and Advanced-Stage HD
Aim: To improve treatment results and minimize acute and late toxicity in patients (pts) with intermediate- or advanced-stage Hodgkin’s disease. A combined modality treatment consisting of a response-adapted chemotherapy (CTX) and radiotherapy (RTX) was used. Conclusions: CEBOPP/VIML followed by RTX appears to be highly effective in achieving long-term…
Cancer
01 Jan 2013
Treatment Stratification According to Early Response to Mega-CHOP
Aim: To assess the efficacy of PBSCT in patients with poor prognosis aggressive NHL according to previous early response to Mega-CHOP evaluated with CT & Ga67S. Those in CR (CT scan, Ga67S negative) or uCR (CT scan positive, Ga67S negative) received a 4th Mega-CHOP followed by BEAM and PBSCT. Those…
Cancer
01 Jan 2013
Factors Affecting HD pts treated with IEGV and HDT with stem cell rescue
Aim: To identify prognostic factors in patients with relapsing/refractory Hodgkin’s Disease treated with IGEV Chemotherapy and High Dose Consolidation Therapy. Conclusions: Based on this analysis, a prognostic model for IGEV-treated patients with refractory/relapsed HD can be constructed using the above factors. Official Title Factors Affecting Outcome of Patients with Refractory/Relapsed…
Cancer
01 Jan 2013
R-GIFOX for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma
Aim: To evaluate the clinical activity, toxicity and mobilizing capacity of a new short-course (bi-weekly), dose intensive, cytoreductive/mobilizing salvage regimen (R-GIFOX) combining the cross-synergistic agents Gemcitabine (G), Ifosfamide (Ifo), Oxaliplatin (Ox) and Rituximab (R) in patients with relapsed and refractory CD20+ NHL. Conclusions: R-GIFOX was feasible, tolerable, effective…
Blood
01 Jan 2013
Comparison between Cy then G-CSF and IVE Plus G-CSF in Haematological Malignancies
Aim: To retrospectively compare the PBPC yields of harvests after IVE with those of standard Cy/G-CSF priming. Conclusions: Priming with IVE yields higher PBPC numbers than cyclophosphamide, patients requiring fewer pheresis, therefore reducing the cost. Official Title A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and…
